Spinocerebellar ataxia 49

disease
On this page

Also known as SCA49

Summary

Spinocerebellar ataxia 49 (MONDO:0030805) is a disease with 1 cohort gene.

At a glance

  • Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
  • Cohort genes: 1
  • ClinVar variants: 40

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Cases/families9WorldwideValidated
Point prevalence<1 / 1 000 000WorldwideValidated

Identifiers

Disease identifiers

FieldValue
Canonical namespinocerebellar ataxia 49
Mondo IDMONDO:0030805
OMIM619806
Orphanet631106
UMLSC5676950
MedGen1805601
GARD0025640
Is cancer (heuristic)no

Also known as: SCA49 · spinocerebellar ataxia 49

Data availability: 40 ClinVar variants · 1 GenCC gene-disease record.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal dominant disease › autosomal dominant cerebellar ataxiaspinocerebellar ataxia 49

Related subtypes (15): GRID2-related autosomal dominant spinocerebellar ataxia, spinocerebellar ataxia 27A, spinocerebellar ataxia 9, spinocerebellar ataxia 43, spinocerebellar ataxia 7, autosomal dominant cerebellar ataxia type I, autosomal dominant cerebellar ataxia type III, autosomal dominant cerebellar ataxia type IV, spinocerebellar ataxia 48, spinocerebellar ataxia 44, spinocerebellar ataxia 47, spinocerebellar ataxia 50, spinocerebellar ataxia 27B, late-onset, spinocerebellar ataxia 51, spinocerebellar ataxia 52

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

40 retrieved; paginated sample, class counts are floors:

22 uncertain significance, 11 conflicting classifications of pathogenicity, 5 benign/likely benign, 1 benign, 1 likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
4056350NM_152703.5(SAMD9L):c.1618A>G (p.Arg540Gly)SAMD9LLikely pathogenicno assertion criteria provided
1017243NM_152703.5(SAMD9L):c.4082T>C (p.Val1361Ala)SAMD9LConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1038336NM_152703.5(SAMD9L):c.1549T>C (p.Trp517Arg)SAMD9LConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1049582NM_152703.5(SAMD9L):c.2069G>A (p.Gly690Asp)SAMD9LConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1049620NM_152703.5(SAMD9L):c.2528G>A (p.Arg843Gln)SAMD9LConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1063306NM_152703.5(SAMD9L):c.854G>A (p.Arg285Gln)SAMD9LConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1520277NM_152703.5(SAMD9L):c.4646T>C (p.Ile1549Thr)SAMD9LConflicting classifications of pathogenicitycriteria provided, conflicting classifications
3617459NM_152703.5(SAMD9L):c.2482C>T (p.Arg828Ter)SAMD9LConflicting classifications of pathogenicitycriteria provided, conflicting classifications
432926NM_152703.5(SAMD9L):c.1877C>T (p.Ser626Leu)SAMD9LConflicting classifications of pathogenicitycriteria provided, conflicting classifications
624284NM_152703.5(SAMD9L):c.3353A>G (p.Tyr1118Cys)SAMD9LConflicting classifications of pathogenicitycriteria provided, conflicting classifications
774190NM_152703.5(SAMD9L):c.1216C>T (p.Arg406Ter)SAMD9LConflicting classifications of pathogenicitycriteria provided, conflicting classifications
813694NM_152703.5(SAMD9L):c.2114A>G (p.Tyr705Cys)SAMD9LConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1015386NM_152703.5(SAMD9L):c.3568G>C (p.Asp1190His)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
1174639NM_152703.5(SAMD9L):c.4140dup (p.Gln1381fs)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
1316334NM_152703.5(SAMD9L):c.1934T>A (p.Leu645Gln)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
1320750NM_152703.5(SAMD9L):c.987del (p.Asp330fs)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
1365897NM_152703.5(SAMD9L):c.683G>A (p.Cys228Tyr)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
1406139NM_152703.5(SAMD9L):c.944T>G (p.Ile315Arg)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
1407336NM_152703.5(SAMD9L):c.1364T>C (p.Val455Ala)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
1410128NM_152703.5(SAMD9L):c.1957T>A (p.Leu653Met)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
1426492NM_152703.5(SAMD9L):c.3410G>A (p.Gly1137Glu)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
1705666NM_152703.5(SAMD9L):c.499C>A (p.Pro167Thr)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
1922426NM_152703.5(SAMD9L):c.853C>T (p.Arg285Trp)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
1959197NM_152703.5(SAMD9L):c.1096T>C (p.Phe366Leu)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
2136077NM_152703.5(SAMD9L):c.4540A>G (p.Lys1514Glu)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
2163451NM_152703.5(SAMD9L):c.994dup (p.Ile332fs)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts
2429769NM_152703.5(SAMD9L):c.3932A>T (p.Asp1311Val)SAMD9LUncertain significancecriteria provided, single submitter
3594950NM_152703.5(SAMD9L):c.4674_4675del (p.Ser1558fs)SAMD9LUncertain significancecriteria provided, single submitter
3594951NM_152703.5(SAMD9L):c.2345T>G (p.Ile782Ser)SAMD9LUncertain significancecriteria provided, single submitter
3594952NM_152703.5(SAMD9L):c.757A>G (p.Lys253Glu)SAMD9LUncertain significancecriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 7 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
SAMD9LDefinitiveAutosomal dominantataxia-pancytopenia syndrome7

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
SAMD9LOrphanet:2585Ataxia-pancytopenia syndrome
SAMD9LOrphanet:619367SAMD9L-associated autoinflammatory syndrome
SAMD9LOrphanet:631106Spinocerebellar ataxia type 49

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
SAMD9LHGNC:1349ENSG00000177409Q8IVG5Sterile alpha motif domain-containing protein 9-likegencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
SAMD9LSterile alpha motif domain-containing protein 9-likeMay be involved in endosome fusion.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
SAMD9LOther/UnknownnoSAM, SAM/pointed_sf

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
buccal mucosa cell1
leukocyte1
pancreatic ductal cell1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
SAMD9L231ubiquitousmarkerpancreatic ductal cell, buccal mucosa cell, leukocyte

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
SAMD9L1,608

Structural data

PDB: 0 · AlphaFold-only: 1 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
SAMD9LQ8IVG583.85

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
SAMD9L00

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1SAMD9L

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
SAMD9L0

Clinical trials & evidence

Clinical trials

Clinical trials: 0.